HC Wainwright & Co. Reiterates Buy on Collegium Pharmaceutical, Maintains $60 Price Target

HC Wainwright & Co. analyst Brandon Folkes has reiterated a Buy rating on Collegium Pharmaceutical (NASDAQ: COLL) and maintained a price target of $60 for the stock. This endorsement reflects confidence in the company's performance and potential for growth.